{"url_path":"/sec/inbx/8-k/2026-06-03/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000030-index.html","accession_number":"0002007919-26-000030","cik":"0002007919","ticker":"INBX","issuer_name":"Inhibrx Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2007919/0002007919-26-000030-index.html","primary_entity_key":"0002007919","primary_entity_name":"Inhibrx Biosciences, Inc."},"word_count":277,"has_tables":true,"body_markdown":"Item 5.07    Submission of Matters to a Vote of Security Holders.\n\nThe 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibrx Biosciences, Inc. (the “Company”) was held on June 3, 2026 at 10:00 a.m. Pacific Time online in a virtual format. Of the Company’s 14,607,286 shares of common stock issued and outstanding and entitled to vote as of the record date of April 7, 2026, a quorum of 11,541,232 shares, or approximately 79% of the outstanding shares entitled to vote, was present virtually or represented by proxy. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 23, 2026. The following actions were taken at the Annual Meeting:\n\nProposal 1\n\nElection of the following nominees as Class II directors of the Company, nominated by the Company’s Board of Directors (the “Board of Directors”), each to serve until the 2029 Annual Meeting of Stockholders and until their respective successor is duly elected and qualified, or until their respective earlier death, resignation, or removal.\n\nVotes ForVotes WithheldBroker Non-Votes\n\nDouglas G. Forsyth7,608,4691,463,4742,469,289\n\nKimberly Manhard9,035,09736,8462,469,289\n\nProposal 2\n\nRatification of the appointment by the Audit Committee of the Board of Directors of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nVotes ForVotes AgainstVotes Abstained\n\n11,510,47830,347407\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDate: June 3, 2026\n\nINHIBRX BIOSCIENCES, INC.\n\nBy:/s/ Leah Pollema\n\nName:Leah Pollema\n\nTitle:VP, General Counsel and Corporate Secretary"}